As­cendis wins ap­proval for once-week­ly growth hor­mone drug as Pfiz­er, Op­ko Health keep up the pres­sure

Den­mark’s As­cendis Phar­ma won its first FDA ap­proval Wednes­day af­ter­noon, beat­ing out a ri­val pro­gram at Pfiz­er for pe­di­atric growth hor­mone de­fi­cien­cy.

As­cendis notched the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER